SCHEMBL3620889

SCHEMBL3620889

C=C(F)c1ccccc1CC(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.39
BCAT2 O15382 1/20 0.38
ATM Q13315 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 1/20 0.37
CTSD P07339 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1567249 0.81 ALDH1A1 (0.60) KDM4EALDH1A1LMNAKMT2AHSD17B10
SCHEMBL10209861 0.81 LMNA (0.47) KDM4EALDH1A1LMNAKMT2AHSD17B10
SCHEMBL3916488 0.81 FOLH1 (0.50) KDM4EALDH1A1LMNAHSD17B10TSHR
SCHEMBL1554320 0.80 KDM4E (0.53) KDM4EALDH1A1LMNAHSD17B10TSHR
SCHEMBL3618346 0.79 BCAT2 (0.54) KDM4ELMNAHPGDBCAT2MAPT
SCHEMBL13687539 0.78 KDM4E (0.43) KDM4EALDH1A1LMNAKMT2AHSD17B10
SCHEMBL11801059 0.78 KDM4E (0.43) KDM4EALDH1A1LMNAKMT2AHSD17B10
SCHEMBL5795352 0.77 AKR1C3 (0.47) KDM4EALDH1A1LMNAKMT2AHSD17B10
SCHEMBL26065127 0.77 KDM4E (0.43) KDM4EALDH1A1LMNAKMT2AHSD17B10
SCHEMBL25673396 0.76 GABRA1 (0.43) ALDH1A1TSHRHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
EP-1904504-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING Methylgene, Inc. (CA) 2008-04-02 EP disclosed
WO-2007054831-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2007-05-18 WO disclosed
WO-2007054831-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2007-05-18 WO disclosed
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, FLT1 KDM4E 4094/4885ALDH1A1 1649/4885LMNA 4411/4885
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling HGF, MET, FLT1 KDM4E 4094/4885ALDH1A1 1649/4885LMNA 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.